Aesthetics

Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study

By April 29, 2020No Comments

Dermatology News

"Safety, Tolerability, and Efficacy of Repeat-Dose Injections of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results from a Prospective, Open-Label, Phase III Study"

IncobotulinumtoxinA (Xeomin/Xeomeen/Bocouture/XEOMIN Cosmetic; botulinum toxin type A free from complexing proteins [150 kDa]; Merz Pharmaceuticals GmbH) is indicated worldwide for the correction of glabellar frown lines (GFL) and in Europe additionally for lateral periorbital lines (LPL; crow’s feet) and upper facial lines (UFL; ie, simultaneous treatment of GFL, LPL, and horizontal forehead lines [HFL]).1

The efficacy of incobotulinumtoxinA in the treatment of multiple or singular facial areas has been extensively demonstrated.2-10 With the recent surge in interest for a more holistic approach, consisting of combined treatment of GFL, HFL, and LPL in a single treatment session, there is a need for demonstrating safety and efficacy for such procedures.

This study provides strong evidence for the safety and tolerability of repeat-dose treatments with incobotulinumtoxinA in UFL (GFL, 20 U; HFL, 10-20 U; LPL, 24 U). A stable safety profile was demonstrated during prolonged administration and a noteworthy trend to better tolerability with continued use of incobotulinumtoxinA was established

Read More

You May Also Like

JDD in the News: Upadacitinib’s Potential Cardiovascular Effects 

| Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
Upadacitinib may provide additional health benefits, including reducing the risk of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). That’s according to a May Journal of Drugs in Dermatology…

Dermatology Roundup: Survey Shows Misconceptions About Sunscreen and Skin Aging

| JDD Highlights, JDD in the Media, The Latest | No Comments
By Allison Sit A new American Academy of Dermatology (AAD) survey shows American adults may not fully understand the benefits of sunscreen. The survey of 1,000 adults found nearly one…

What’s Old is New: The Translational Understanding of and Approaches to Dermatoporosis

| JDD Highlights, JDD Webinars, The Latest | No Comments
This webinar delves into the emerging field of dermatoporosis, a chronic skin fragility condition. Participants will explore the latest translational research that bridges basic science and clinical practice, enhancing our…

Leave a Reply